308 related articles for article (PubMed ID: 36082178)
1. Anti-TNF-α agents for refractory intestinal Behçet's disease: case series and meta-analysis.
Zhan S; Liu C; Li N; Li T; Tian Z; Zhao M; Wu D; Chen M; Zeng Z; Zhuang X
Therap Adv Gastroenterol; 2022; 15():17562848221116666. PubMed ID: 36082178
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Anti-Tumor Necrosis Factor-Alpha Agents for Patients with Intestinal Behcet's Disease: A Systematic Review and Meta-Analysis.
Zhang Q; Ma C; Dong R; Xiang W; Li M; Ma Z; Yang Q
Yonsei Med J; 2022 Feb; 63(2):148-157. PubMed ID: 35083900
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of anti-tumor necrosis factor agents in the treatment of intestinal Behcet's disease, a systematic review and meta-analysis.
Zhang M; Liu J; Liu T; Han W; Bai X; Ruan G; Lv H; Shu H; Li Y; Li J; Tan B; Zheng W; Xu H; Zheng W; Yang H; Qian J
J Gastroenterol Hepatol; 2022 Apr; 37(4):608-619. PubMed ID: 34894004
[TBL] [Abstract][Full Text] [Related]
4. Update on the Treatment of Behcet's Disease of the Small Bowel with Biologic Agents.
Park Y; Cheon JH
Curr Gastroenterol Rep; 2020 Mar; 22(5):24. PubMed ID: 32193746
[TBL] [Abstract][Full Text] [Related]
5. Clinical manifestations and anti-TNF alpha therapy of juvenile Behçet's disease in Taiwan.
Hu YC; Yang YH; Lin YT; Wang LC; Yu HH; Lee JH; Chiang BL
BMC Pediatr; 2019 Jul; 19(1):232. PubMed ID: 31296171
[TBL] [Abstract][Full Text] [Related]
6. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
Sugimura N; Mizoshita T; Sugiyama T; Togawa S; Miyaki T; Suzuki T; Tanida S; Kataoka H; Sasaki M
Dig Liver Dis; 2019 Jul; 51(7):967-971. PubMed ID: 30872086
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of a refractory intestinal Behcet's disease with an oncology history by Vedolizumab: a case report and literature review.
Li R; Li X; Zhou H; Shi Y; Wang F; Wu T; Liang J
Front Immunol; 2023; 14():1205046. PubMed ID: 37287984
[TBL] [Abstract][Full Text] [Related]
8. Treatment with Biologic Drugs in Pediatric Behçet's Disease: A Comprehensive Analysis of the Published Data.
Batu ED; Sener S; Cam V; Aktay Ayaz N; Ozen S
BioDrugs; 2023 Nov; 37(6):813-828. PubMed ID: 37382804
[TBL] [Abstract][Full Text] [Related]
9. The real-world use of different anti-tumor necrosis factor agents in a Northern European population of patients with Behçet's disease.
Adeeb F; Ng WL; Khan MU; Devlin J; Stack AG; Fraser AD
Eur J Rheumatol; 2017 Dec; 4(4):254-259. PubMed ID: 29308279
[TBL] [Abstract][Full Text] [Related]
10. The Efficacy of Medium- to Long-term Anti-TNF-α Antibody-based Maintenance Therapy in Behçet's Disease Patients with Intestinal Lesions.
Kambayashi H; Omori T; Saito S; Murasugi S; Kashiwagi H; Ito A; Yonezawa M; Nakamura S; Tokushige K
Intern Med; 2020; 59(19):2343-2351. PubMed ID: 32999263
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and predictor of anti-TNFα agents in patients with intestinal Behçet's disease.
Miyazaki H; Watanabe D; Okamoto N; Tokunaga E; Ku Y; Takenaka H; Hoshi N; Ooi M; Kodama Y
BMC Gastroenterol; 2022 Mar; 22(1):149. PubMed ID: 35346067
[TBL] [Abstract][Full Text] [Related]
12. Risk Factors for Surgery in Patients with Intestinal Behçet's Disease During Anti-Tumor Necrosis Factor-Alpha Therapy.
Han SJ; Kang EA; Park J; Park SJ; Park JJ; Kim TI; Kim WH; Cheon JH
Yonsei Med J; 2023 Feb; 64(2):111-116. PubMed ID: 36719018
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy, safety, and cumulative retention rate of antitumor necrosis factor-alpha treatment for patients with Behcet's uveitis: A systematic review and meta-analysis.
Guan X; Zhao Z; Xin M; Xia G; Yang Q; Fu M
Int J Rheum Dis; 2024 Feb; 27(2):e15096. PubMed ID: 38402428
[TBL] [Abstract][Full Text] [Related]
14. Updated treatment strategies for intestinal Behçet's disease.
Park YE; Cheon JH
Korean J Intern Med; 2018 Jan; 33(1):1-19. PubMed ID: 29207867
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumour necrosis factor-alpha agent therapy, compared with conventional therapy, reduces the relapse of uveitis in patients with behçet's disease: A systematic review of controlled trials.
Zhou X; Shi X; Ren Y; Yan T; Ye Q
Front Pharmacol; 2022; 13():912906. PubMed ID: 36060006
[No Abstract] [Full Text] [Related]
16. Adalimumab in the management of Behçet's disease.
Ueda A; Takeno M; Ishigatsubo Y
Ther Clin Risk Manag; 2015; 11():611-9. PubMed ID: 25926738
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab for the treatment of Japanese patients with intestinal Behçet's disease.
Tanida S; Inoue N; Kobayashi K; Naganuma M; Hirai F; Iizuka B; Watanabe K; Mitsuyama K; Inoue T; Ishigatsubo Y; Suzuki Y; Nagahori M; Motoya S; Nakamura S; Arora V; Robinson AM; Thakkar RB; Hibi T
Clin Gastroenterol Hepatol; 2015 May; 13(5):940-8.e3. PubMed ID: 25245624
[TBL] [Abstract][Full Text] [Related]
18. Advances in Management of Intestinal Behçet's Disease: A Perspective From Gastroenterologists.
Cheon JH
J Rheum Dis; 2021 Jan; 28(1):4-16. PubMed ID: 37476392
[TBL] [Abstract][Full Text] [Related]
19. Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report.
Gulli S; Arrigo C; Bocchino L; Morgante L; Sangari D; Castagna I; Bagnato GF
BMC Musculoskelet Disord; 2003 Aug; 4():19. PubMed ID: 12946278
[TBL] [Abstract][Full Text] [Related]
20. Brief Report: Drug-Free Long-Term Remission in Severe Behçet's Disease Following Withdrawal of Successful Anti-Tumor Necrosis Factor Treatment.
Sfikakis PP; Arida A; Panopoulos S; Fragiadaki K; Pentazos G; Laskari K; Tektonidou M; Markomichelakis N
Arthritis Rheumatol; 2017 Dec; 69(12):2380-2385. PubMed ID: 28834393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
